NTLA Q4 2020 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-39.7% YoY

Gross Profit

-$32M-479.7% margin

Operating Income

-$42M-642.9% margin

Net Income

-$42M-639.8% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-70.3%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$41M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$676M

Total Liabilities

$149M

Stockholders' Equity

$527M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$11M	-39.7%
Gross Profit	-$32M	-$21M	-52.1%
Operating Income	-$42M	-$30M	-42.4%
Net Income	-$42M	-$28M	-49.2%